| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/JAC/DKW297 |
| P8608 | Fatcat ID | release_lzqmzvczazh5fn5bc6yx4hhzzu |
| P932 | PMC publication ID | 5079302 |
| P698 | PubMed publication ID | 27521357 |
| P50 | author | Juergen Bulitta | Q52063271 |
| Cornelia Barbara Landersdorfer | Q56769943 | ||
| Vanessa E Rees | Q60621528 | ||
| Craig R Rayner | Q97641254 | ||
| P2093 | author name string | Antonio Oliver | |
| Roger L Nation | |||
| Brian T Tsuji | |||
| P2860 | cites work | Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis | Q24200604 |
| Combating antimicrobial resistance: policy recommendations to save lives | Q24632857 | ||
| Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system | Q28477067 | ||
| The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants | Q28492576 | ||
| Induction of the MexXY efflux pump in Pseudomonas aeruginosa is dependent on drug-ribosome interaction | Q28492803 | ||
| Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis | Q28492843 | ||
| Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model | Q33826267 | ||
| Mucoidy, quorum sensing, mismatch repair and antibiotic resistance in Pseudomonas aeruginosa from cystic fibrosis chronic airways infections | Q34117477 | ||
| Aminoglycoside adaptive resistance: importance for effective dosage regimens | Q34277787 | ||
| Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations | Q34476089 | ||
| High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. | Q34508854 | ||
| Pseudomonas aeruginosa: resistance to the max | Q35084559 | ||
| Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling. | Q35168882 | ||
| Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance | Q35432770 | ||
| Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. | Q35826231 | ||
| Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. | Q35879111 | ||
| Aminoglycoside resistance in Pseudomonas aeruginosa | Q36021296 | ||
| Surface action of gentamicin on Pseudomonas aeruginosa | Q36122071 | ||
| MexXY multidrug efflux system of Pseudomonas aeruginosa | Q36450695 | ||
| Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study | Q36536423 | ||
| First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. | Q36752618 | ||
| Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design | Q36785827 | ||
| Evolving problems with resistant pathogens | Q37101715 | ||
| Multiple mutations lead to MexXY-OprM-dependent aminoglycoside resistance in clinical strains of Pseudomonas aeruginosa | Q37544527 | ||
| Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections | Q37598703 | ||
| Mutators in cystic fibrosis chronic lung infection: Prevalence, mechanisms, and consequences for antimicrobial therapy | Q37788421 | ||
| Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance | Q37794342 | ||
| Pharmacological considerations for the proper clinical use of aminoglycosides | Q37956403 | ||
| Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure. | Q39557669 | ||
| Development of resistance during antibiotic therapy | Q39665988 | ||
| MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. | Q39743310 | ||
| Use of the fluorescent probe 1-N-phenylnaphthylamine to study the interactions of aminoglycoside antibiotics with the outer membrane of Pseudomonas aeruginosa | Q39849104 | ||
| Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa | Q39855013 | ||
| Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. | Q39881843 | ||
| Onset of penicillin-induced bacteriolysis in staphylococci is cell cycle dependent | Q39948722 | ||
| Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. | Q40827402 | ||
| Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation | Q41366386 | ||
| Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 | ||
| Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections | Q41974061 | ||
| Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. | Q41987074 | ||
| Antibiotic resistance: An infectious arms race. | Q42217180 | ||
| Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa | Q43215544 | ||
| Antibiotic inducibility of the mexXY multidrug efflux operon of Pseudomonas aeruginosa: involvement of the MexZ anti-repressor ArmZ. | Q43245264 | ||
| Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial | Q45262881 | ||
| Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis | Q46172261 | ||
| Public health: The politics of antibiotics. | Q46198502 | ||
| Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair | Q46617407 | ||
| High mutation frequencies among Escherichia coli and Salmonella pathogens | Q48057867 | ||
| Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. | Q54319060 | ||
| Correlation between bactericidal activity and postantibiotic effect for five antibiotics with different mechanisms of action. | Q54562999 | ||
| Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa | Q57240410 | ||
| Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations | Q57240418 | ||
| Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore | Q58033538 | ||
| Postantibiotic effect of aminoglycosides on gram-negative bacteria evaluated by a new method | Q70405372 | ||
| Postantibiotic suppression of bacterial growth | Q71543981 | ||
| The effect of aminoglycoside-induced adaptive resistance on the antibacterial activity of other antibiotics against Pseudomonas aeruginosa in vitro | Q71876778 | ||
| Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro | Q72196470 | ||
| Mechanisms of antibiotic resistance in Pseudomonas aeruginosa | Q74746286 | ||
| Impact of pharmacokinetics on the postantibiotic effect exhibited by Pseudomonas aeruginosa following tobramycin exposure: application of an in-vitro model | Q77075520 | ||
| Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? | Q80050474 | ||
| Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis | Q84219534 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Pseudomonas aeruginosa | Q31856 |
| P304 | page(s) | 3157-3167 | |
| P577 | publication date | 2016-08-11 | |
| P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
| P1476 | title | Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa | |
| P478 | volume | 71 |
| Q40265579 | Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility |
| Q52685491 | Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy. |
| Q90230125 | Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable Pseudomonas Aeruginosa Strains via Mechanism-Based Modelling |
| Q57240383 | Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis |
| Q92127147 | Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans |
| Q37389435 | Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock. |
| Q90050041 | Levofloxacin-ceftazidime administration regimens combat Pseudomonas aeruginosa in the hollow-fiber infection model simulating abnormal renal function in critically ill patients |
| Q58164270 | Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients |
| Q57169588 | Meropenem combined with ciprofloxacin combats hypermutable from respiratory infections of cystic fibrosis patients |
| Q49792113 | Optimization and evaluation of piperacillin plus tobramycin combination dosage regimens against Pseudomonas aeruginosa for patients with altered pharmacokinetics via the hollow-fiber infection model and mechanism-based modeling |
| Q50044377 | Optimization of a meropenem plus tobramycin combination dosage regimen against hypermutable and non-hypermutable Pseudomonas aeruginosa via mechanism-based modeling and the hollow-fiber infection model. |
| Q40306198 | Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model |
| Q92707838 | Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model |
Search more.